^(99)Tc-MDP缓解乳腺癌芳香化酶抑制剂辅助内分泌治疗后骨关节、肌肉痛的疗效分析

A clinical study for ^(99)Tc-MDP in the relief of pain due to breast cancer with aromatase inhibitor adjuvant endocrine therapy

目的应用99Tc-MDP治疗乳腺癌芳香化酶抑制剂(AI)辅助内分泌治疗后骨关节、肌肉痛,探讨其临床价值。方法收集2003年1月至2007年3月间乳腺癌AI辅助内分泌治疗后骨关节、肌肉痛患者74例,随机分为二组:99Tc-MDP加服钙尔奇D组(A组)34例,单服钙尔奇D组(B组)40例。比较两组对疼痛的缓解效果。结果骨关节、肌肉痛症状缓解情况:A组总有效率为94.1%,B组为52.5%,两组差异有统计学意义(P<0.001)。结论99Tc-MDP使用简便、安全、疗效满意、不良反应少,值得临床推广应用于缓解绝经后乳腺癌AI辅助内分泌治疗后的骨关节、肌肉痛。

Objective To evaluate the safety and efficacy of ^99Tc-MDP to relieve pain due to breast cancer with aromatase inhibitor endocrine therapy. Methods From January 2003 to March 2007,74 patients of breast carcinoma with endocrine therapy felt pain in bone, arthrosis or/and muscle, who were randomized to A or B group. 34 cases in group A（^99 Tc-MDP＋ Cahrate with vitamin D 600 Tablets） , 40 cases in group B（ Caltrate with vitamin D 600 Tablets）. The relief of pain between two groups was compared. Results Patients in group A showed an overall response rate of 94. 1% , compared with 52. 5 % in group B （ P 〈 0. 001 ）. Conclusion ^99 Tc-MDP is a convenient, safe, effective and little adverse drug, and worthy to apply in the relief of pain due to breast carcinoma with endocrine therapy.